ArticleJournal of gastrointestinal cancer2025
U.S. Colorectal Cancer Mortality, 1999-2023: A 25-Year National Analysis of Trends and Disparities.
Article in Journal of gastrointestinal cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundColorectal cancer (CRC) remains the third leading cause of cancer-related deaths in the United States. Although diagnostic and treatment improvements have reduced overall mortality, disparities persist across populations and regions.
methodsWe analyzed the Centers for Disease Control and Prevention Wide-ranging Online Data for Epidemiologic Research (CDC WONDER) database (1999-2023), calculating age-adjusted mortality rates (AAMRs) per 100,000 and average annual percent change (AAPC), stratified by age, sex, race, urbanization, and state.
resultsFrom 1999 to 2023, the overall AAMR for CRC declined by 38.9 percent, from 32.06 to 19.57 per 100,000 (AAPC: -2.08). However, disparities remain. In 2023, males had an AAMR of 23.23, which was 41.1 percent higher than that of females at 16.45. Non-Hispanic (NH) Black individuals had the highest mortality (AAMR: 24.90). Among adults aged 35 to 44, the AAMR rose from 2.87 to 3.71 (AAPC: 1.03), marking a 29.3 percent increase. Nonmetropolitan areas had a 24.0% higher mortality rate than metropolitan areas, with AAMRs of 23.16 and 18.69, respectively. Southern states such as Texas and Georgia saw notable increases in death counts, rising by 34.1 and 38.7 percent, respectively.
conclusionDespite overall progress, rising mortality in adults under 55 and certain racial groups signals an urgent need for targeted action. Recommendations include refining racial categories in national data, expanding screening in high-risk states with slower mortality declines, and providing mobile screening units in rural areas with consistently high AAMR. Additionally, recovery efforts should address COVID-19-related backlogs in screening, diagnostic colonoscopy, and timely treatment.
Indexed as
Identifiers
41457141What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.